Press releases

VALBIOTIS will present the results of its Phase I/II clinical study on the active ingredient of Valedia®, Totum-63, during the 77th Scientific Sessions of the American Diabetes Association.

June 9th 2017

The results, which validate the safety and a first proof of efficacy for Valedia®, will be presented during a poster session on 11 June from 12 pm to 1 pm (Hall B).

Read more

VALBIOTIS INITIAL PUBLIC OFFERING RECORDS HUGE SUCCESS

June 2nd 2017

VALBIOTIS has announced today the huge success of its initial public offering and the admission of its shares for trading on Alternext Paris (ISIN code: FR0013254851 and mnemonic code: ALVAL).

Read more

SEBASTIEN PELTIER PRESENTS HIS VISION OF A DIABETES-FREE WORLD AT L’ÉCHAPPÉE VOLÉE

April 24th 2017

Sébastien Peltier has been selected to share his vision of a diabetes-free world at l’Echappée Volée. This is a major event that fosters useful, breakthrough innovation for the common good, in preparation for the next 15 to 20 years.

Read more

TWO PARTNERSHIP AGREEMENTS TO ASSESS THE EFFECTS OF TOTUM-63, THE ACTIVE INGREDIENT OF VALEDIA®, ON INTESTINAL MICROBIOTA

April 12th 2017

VALBIOTIS, a company that specializes in developing innovative nutrition solutions designed to prevent cardiometabolic diseases and provide nutritional support for patients, has announced today the signing of two partnership agreements, one with Biofortis (Merieux NutriSciences), and the other with the Université Catholique de Louvain (Belgium) and Prof. Patrice D. Cani1 (PhD) as part of a program aimed at evaluating the efficacy of TOTUM-63, the active ingredient of Valedia®, on intestinal microbiota.

Read more